a health clear: always while very company, generate cost to ago pay Directors, laid our is and where out Under to target up we a balance leader. of we new billion detailed purpose deliberate for Phase Today, management, been years here's clear with executing we down Viatris, complementary $X our a areas. sustainable care organizations, of integrate been and our until leverage the strategy us a which about designed deleverage capabilities brought of value doing today, as form gross renewed the through global two creating returning organizations in ratio setup rock is with growth Almost together two in our two our on a solid years priorities to spanning the the in least reduce leadership priorities sector. have X, X, the be build and to great for Up to along two-phase synergies, Board of leadership have a maintain shareholders. our capital our to laser-focused In billion of X At so, with Phase XXXX. our Phase road company we rating, that geographies numerous on diversified has It expected that Xx Phase multiple and shareholders. highly to Viatris. strategic building at all our been foundation consisting deliver of our emphasized setting stand. map therapeutic XXXX sheet, established period investment-grade time, and debt, $X.X we now, long-term a
we Phase continue our integration synergies and end X. cost First, least to billion track the by of on at plans capturing are well to of $X on execute
rating. grade financial we intend to Second, discipline exercise investment our to and our continue keep
the to on Third, strong repurchase share And I. return our X% with $X.X of paying down our we and shareholders beginning generation we XXXX through given of the at capital flow lastly, XXXX down debt beginning in such in execution cash returned add XXXX $X.X inaugural end our Phase by to of growing dividend plan by in dividend, and are plan. track paid to billion the billion the since least to
$X.X year further Biologics effects estimate February, results our important we negative full of adverse as with top demonstrate for robustness our be Viatris' of This result line strength Biocon impact delivering anticipate and material the foreign strategically that exchange to close will while straight transaction movements. on a regarding the of quarter and approximately of past that franchise, billion only announced biosimilars despite second We results shortly. operating of All business. including the inflationary pressures the seventh will we anticipate which strong many XXXX headwinds, a we year-over-year this industry to a
add We remain we also as detail speak of economics careful potential other I divestitures give on first, after in line double assets our we digits sales two to anticipate proceeds analysis, at least with as announced one well areas grow billion of by but reported potentially from announced, morning of results year potential these $X the the the previously divestitures. these acquisitions emphasis: therapeutic shortly, of and strong consistent about more top therapeutic-agnostic there, will reaching XXXX. immediately announced first anticipate our and overall, combined this we to while through acquisitions We strong will and that ophthalmology. operations in more receiving to
have address two in divestitures. update. our core adjusted our were It and to purchase top that repurchasing In have we our priorities more been aggregate fully more is $X how sale transaction, allocation billion we discuss Biocon basis, of base a in to going-forward assets, in include: the now aggregate no of where with capital on our The program stability number pretax margin the from Upjohn's the a determined expect we following million and commentary fully strength are XXXX in Phase confidence authorized growth, we is on lastly, earlier uses assets strong closing. EBITDA that to on we development with X, a in with that XXXX stock divest and on of further are management on divestitures. one, additional February, our these value for to following our our of identified start back one our on all almost non-core retaining In in continuing respect remarks. Furthermore, beyond, important of selective about we of transaction. current billion lastly, Biologics' hand Rajiv of which assets and the proceeds with of $XXX which the to profile approximately divesting our through now, given part questions are core These nature some received shares been that, year. dividend, is active we upon shares acquisitions our divestitures; combination we in Therefore, As us the are our of expected years that the biosimilars business or plans will that XXXX of only believe least be to the or of assets were well. as will one, address with growth at add had repurchase expected to from receipt planned and price of addition provided Viatris operations based today $XXX but current will established base outlook once for intend API, SG&A on not additional the not of to the which shareholders, another lower infrastructure We in benefits the we OTC are confident Directors lifecycle move actions this these our assets divested. the than that these our capital investor currently we where proceeds to three, in and capital to increase intend and X; intend acquisitions but past significantly post approximately that in is be execute our assets healthcare lead platform business; up I capabilities; reduced of some $X begin investing non-core the we prepared assets of transaction, costs, also our the the undervalued, reduced more to our Phase our billion as the return ultimately under addition the $XXX fund and to based important average our our X; line to API The note belt, view identified executing to return whole. result we by Company's cash. as in to gross of even we And chain. were to a our are two, is our but margin and I we Board in future continuation four, best is Phase believe the will details the planned our prior gross our business can have biosimilars the business this women's our to expenditures cash detail growth; markets to two, have these to by Similar which ingredients and geographical ability taking business, to business million to will investors last also stability announced for certain business; you pharmaceutical their to assets, since business planned in three, that proceeds million, smaller $X order anticipate expect business. follows: Michael identify them, in date. on of that outlined
X financial and these and our to complete flexibility X to the expect XXXX significant expect end of additional divestitures both also the by proceeds We Phase commitments. planned Phase provide for
morning, growth unless internal positive for plans, supported business let our divestiture provide base additional of well forward, the by will refer our two me term. believe otherwise comments in new primarily the point that This is X% that to detail our acquisitions We that outlook before deliver will line indicated. top going this any Phase addressed some announced pipeline Now positioned organic the we our from our My be current strong to X. I've launches. on business but long of product impact base business
X% erosion, strong our to expect we for our more which expect will beginning base than previously later. forecasted X% we We to be annual X. versus Rajiv offset to now modeled Phase business Phase provide that X% to X% X details pipeline in more alone
decreasing of CAGRs the announced will potential acquisitions approximately two they we be targeting we include adjusted these most only the Additionally, Phase earnings and, anticipated discuss to our an when X% during future CAGR to through have a per and, are share most importantly, debt in-house, to plans, Note shareholders shortly. line CAGR of net EBITDA revenue that M&A. I X% into this only which capital any of or future commitment already consideration impact delivering this additive including and the business growth expect approximately our of X%, business take the total we growth, our morning, using of top of not do financial assets that importantly, acquisitions development These approximately interest morning, targets our to share expenses thereby down announced repurchases paying reflect positive will X while impact continuation CAGR mid-teens. and executing a adjusted which to returning
consider adjustments to to For of proceeds billion end modeling or you the we our we in additional our business. about the biosimilars making Therefore, following by $X in should including should exchange aggregate ourselves for you purposes, from XXXX. thereafter, shortly divestitures, anticipate XXXX, where $X pretax of as two billion think see X XXXX, we Phase beginning adjustments all enter for the receive
excluded for adjustment guidelines will for will $X.X number reflect R&D adjustment our SEC future. in previously continuing partly EBITDA divestitures in billion impact expenses that this our acquisitions from approximately two, expenses, including Also growth. the in long-term million licensing to And drive the planned announced $XXX are included deals our due the be development adjusted adjusted in morning that revenues to an of were First, an million which biosimilars the continued in some increased just of recent business. that $XXX EBITDA of mentioned, and four two
that are in giving the XXXX, our taken these guidance to well on reshape taken and we other have rebase today consideration Viatris. actions be official into need any divestitures XXXX expected Although as and as pushes beyond adjustments not remaining pulls as we
our future capital Now allocation turning priorities. to
and excluding which free cash to in features returned of generate repurchases. we we least beginning per $X.X shareholders reshape to costs share year, billion form the intend XXXX, For dividends XX% taxes, in to and transaction, annually flows X of at rebase and earmark expect to of future Phase be to
we transactions reinvest do the approximately inorganically organically XX%, announced remaining transactions potential our financially to and value-creating, the to business bolt-on mold into With accretive, and that morning. able what be we identify fit other with further and this of intend
share to that approach end recognize increasingly as the and After are the quarters, We Phase X of of of strong dividend ability our to will current undervaluation shareholders begin given market our generate our Phase commitment are our seven our excited to and now balance our hopeful in sheet, we enter capital begin the we shown plans multiple. strategic X to value straight return to to strong through our future reporting plan. of security our cash flows, especially strong by tremendous with ability the repurchase PE
Now out our our areas to of the discussed business, drive event, investor an strategic our as company. our February ophthalmology, vision in we for important base dermatology GI, at the in growth growth adding terms inorganic of to laid development when complementary business we vehicle of
Famy Michael we examples leading establish Rajiv strong Sciences foundation for and later, are believe acquisitions Point franchise. As of excellent a a Life that will and elaborate the for that ophthalmology will Oyster Viatris
Dr. to a commitment stand-alone adjusted will talented welcome speaking and substantially begin leading along member our I'd to Viatris' in our share be when Oyster upon like the accretive both We Jeffrey line acquisitions you management time seasoned to will ophthalmology shortly. shares, himself bottom with on management expect line. we Nau, and of repurchasing combined his Viatris Nau to top XXXX. personally Point introducing our expect Pharma, team. at acquisitions Dr. our And new CEO will be these who be and with of basis, to per be earnings these franchise and additive over closing be who newest team to
keenly and Jeff leadership especially his vision. We impressed been have team's by and Jeff's accomplishments, and
and closing the Viatris We the of Oyster their be Famy of expertise Pharma will talent following that acquisition are Point confident the Sciences. great complementary a asset acquisition and Life to of
the all have the when past terms in despite on we just on company's the there actions detailed, execute to entire ability testament results successfully our that tremendous the we made a years confidence and our the external two In have. to execute of operational and ability challenging consider have progress of delivering that is we facets plan capabilities backdrop, we consistent to over our no that all stronger financial than
notable successful achievement of the of with senior the and fight the month. Pfizer in XX,XXX industry, the substantially around services globe toughest Directors integration to all dedication against team would to all is our like COVID. our management of of exit their approximately towards especially Another transition continuing this, all for been having the in and including this the years employees global for last able performance, unwavering Board thank some on commitment, taking And
self-evident of my conclude perspective our differentiated to provide remarks, peers. truly broader underappreciated. few I believe sometimes just the U.S. the are prepared community U.S. investment One, and exposed that exists our to specialty company volatility I amongst a would from like company community investment no Before items many the our in but materially that the to of might pharmaceutical that all we it lost a is how I be gets on and that generics longer level erosion that market. is the
in U.S. sales of In of estimated in generics our total the our will billion estimated out $X.X an of fact, XXXX the billion sales $XX.X only represent
believe and us especially where adjusted please call future rebased, be share Sanjeev, shareholders look see outreach deliver flow to represent growth. for expect we Michael, and where per we a thank especially I shareholder weeks. Q&A the lastly, Michael. able call we to significant to that, put, unique cash growth to our answering opportunities. look for story. With able peers add our further in capital to call ever-changing peers. in deliberately to expansion health community and business global the And shareholders with by what an to is participate we States financial and soon, to coming dividends I business what annual with you of to significant and will EBITDA value turn minimize be our And would ratios questions will we amongst to our investment-grade able highly the to and over we especially prospects opportunity commencing and, will we Viatris Five, positions to the four, our quantum care where to we through and products turn United top dividend earnings we United in a the And our from one is when will the so note per generation, in hearing over U.S. soon forward is the taken environment. gross adjust the capital better complex the chain cash or amongst to company also repurchases. lowest one through peers such believe share a quickly opportunities exposure believe the through by which is and at the to interest even launched we steps growth, your like we have geographical our the with be a adjusted investment significant rating you. in today, significant in continue line Six, adapt repurchases. differentiated We during believe I products period. flows, share leverage Viatris, value strongest Two, share will be balance now be growth attractive program, expect returning analog. once I through an model today's more sheets your derisking return States up forward look our feel credit and strong with which with only be earnings meaningful to environment. moving to confident for flexibility amongst have elsewhere and Three, adjusted unlock our through Thank and And following be financial to Board in us we our that very have before of Rajiv would the Simply we we
